AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06504459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05712096 — intervention group
Intervention type: DRUG
Intervention: EVUSHELD
Description: EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
Study NCT04685135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: 21 day cycles
Study NCT04685135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 21 day cycles
Study NCT05588388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
Study NCT04680715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Per-Operative Radiotherapy technique by Papillon +TM
Description: 20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
Study NCT05409573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double monitoring of EtO2
Description: A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)
Study NCT06205602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117-LS
Description: 30 mg/kg to be administered via IV at Step 1 (Day 1)
Study NCT06205602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-1074-LS
Description: 10 mg/kg to be administered intravenously at Step 1 (Day 1)
Study NCT06205602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 3BNC117-LS
Description: 0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
Study NCT06205602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 10-1074-LS
Description: 0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
Study NCT06212453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Microwave Ablation
Description: 3D ultrasound-guided focal thermal ablation of the prostate transition zone
Study NCT05718570 — intervention group
Intervention type: DRUG
Intervention: Somapacitan
Description: Sogroya therapy in participants with AGHD.
Study NCT06585410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered per protocol
Study NCT06585410 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Primary surgery
Study NCT04779320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV
Study NCT05831579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton GRID Radiotherapy
Description: The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
Study NCT04947124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101ophthalmic solution 1%
Description: QLS-101ophthalmic solution 1.0%
Study NCT04947124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101ophthalmic solution 2%
Description: QLS-101ophthalmic solution 2.0%
Study NCT05996406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400mg po qd for 1 year
Study NCT05996406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Immunotherapy
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Immunotherapy
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Immunotherapy
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Immunotherapy
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT05715229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy
Study NCT06110273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit for Duty-mobile
Description: Fit for Duty-mobile participants will receive self-regulatory support and behavior change techniques via an initial core intervention delivered through a native smartphone app (includes connected device data, 10 weekly lessons, weekly tailored feedback) and 4 coaching calls (weeks 1, 4, 8, and 16). App based tailored feedback and messaging will continue through 2 years. Optional 4-week refresher e-campaigns are offered every 6 mos. after the initial core intervention. Participants choose to follow either a Small Changes approach or a Large Changes approach and may choose to switch approaches over the 2 years, if desired.
Study NCT06110273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: m-Health Control
Description: Participants receive digital tools and education on weight gain prevention behaviors at baseline.
Study NCT06220851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Handgrip strength
Description: Handgrip strength will be measured by 3 efforts.
Study NCT06293378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine enteric-coated tablets
Description: 1. Cohort A: PBC treatment group: (1) PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA（13-15mg/kg）, 30 patients took UDCA（13-15mg/kg）+SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months, and 12 months of follow-up observation.~(2) Newly treated PBC patients: 30 patients took UDCA（13-15mg/kg） and 30 patients took UDCA（13-15mg/kg）+SASP (0.5g orally three times a day) for 12 months and were followed up for 12 months.~2. Cohort B-D: 60 cases were collected from each group, 30 cases continued the current treatment(people with hepatitis B cirrhosis and hepatitis C cirrhosis continue to take antivirals), and 30 patients were taking sulfasalazine for 12 months of follow-up observation.~After 12 months of treatment, at the time of enrollment and the 1st/2nd/3rd/6th/9th/12 months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected。
Study NCT04979416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video messages
Description: video messages aimed at increasing vaccination
Study NCT04356287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
Study NCT04356287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each infusion will consist of 50 mL of PlasmaLyte A.
Study NCT05207527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiovascular exercise
Description: Exercise that mainly stimulates the cardiovascular and respiratory systems.
Study NCT05207527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength
Description: Exercise that primarily stimulates the musculoskeletal system.
Study NCT06578247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Participants will receive quizartinib at 60 mg/day orally once daily
Study NCT06578247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo at 60 mg/day orally once daily
Study NCT05207527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed
Description: Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
Study NCT06578247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo at 60 mg/day orally once daily
Study NCT06578247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Study NCT06578247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody therapy
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD38 antibody therapy
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy
Study NCT06015048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 combined with Pyrotinib.
Description: SHR-A1811 combined with Pyrotinib
Study NCT06015048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 combined with other antitumor therapies
Description: SHR-A1811 combined with other antitumor therapies
Study NCT05782790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation Theraphy Group
Description: In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
Study NCT05782790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic Swallowing Exercise Group
Description: Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
Study NCT06206395 — intervention group
Intervention type: DEVICE
Intervention: Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging
Description: 2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment.
Study NCT04782726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software Solution for Radiation Therapy Treatment
Description: Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
Study NCT04782726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiation therapy
Description: Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
Study NCT04782726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
Study NCT05635149 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
Study NCT04998409 — intervention group
Intervention type: DEVICE
Intervention: Monofocal lens
Description: not applicable as patients are already implanted with the monofocal lens
Study NCT05223556 — intervention group
Intervention type: DEVICE
Intervention: Full Self-Diagnostic device in a remote diagnostic imaging site
Description: Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
Study NCT05223556 — intervention group
Intervention type: DEVICE
Intervention: Human imager operated diagnostic device in the hospital
Description: Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
Study NCT05224895 — intervention group
Intervention type: PROCEDURE
Intervention: General Anesthesia in Trendelenburg position for robotic prostatectomy
Description: in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
Study NCT06408909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Intervention Group
Description: Group to which the clinical pharmacist makes recommendations The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
Study NCT04800588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: California Cognitive Assessment Battery
Description: The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
Study NCT06262711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).
Study NCT06262711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).
Study NCT05441553 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGB-R04
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
Study NCT06360965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Improved warm meridians and relieve pain plaster
Description: Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
Study NCT06360965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional warm meridians and relieve pain plaster
Description: The treatment course is the same as the improved warm meridians and relieve pain plaster group.
Study NCT06360965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plaster
Description: The treatment course is the same as the improved warm meridians and relieve pain plaster group.
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Excersises
Description: Active thumb exercises
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Excersises
Description: Active thumb exercises
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reeducation ADL
Description: Reeducation in the activities daily life
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reeducation ADL
Description: Reeducation in the activities daily life
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint protection
Description: Used of a thumb orthosis
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint protection
Description: Used of a thumb orthosis
Study NCT04819139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: Specific proprioception exercises
Study NCT06521190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACOU085 (bimokalner)
Description: Transtympanic injection
Study NCT06521190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transtympanic injection
Study NCT06483906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Azacitidine and Homoharringtonine
Description: Patients will receive the VAH regimen for the treatment of AML
Study NCT05547256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose
Description: 50μg/dose
Study NCT05547256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose
Description: 100μg/dose
Study NCT05547256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution
Study NCT06597292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision improvement
Description: Vision improvement for patients with refractive disorders (hyperopia and presbyopia)
Study NCT06609200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Study NCT06609200 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Study NCT06612138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercises
Description: the patients will receive pilates exercises in the form of breathing exercises, chest lift, bridging, mermaid, swan, quadruped exercises
Study NCT06612138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga exercises
Description: the patients will receive yoga in the form of Bhastrikā: rapid and powerful inhalations and exhalations by means of the force of the diaphragm, letting the air sound when exhaling, Nāḏī Śoḏhana: from Sanskrit, nadi means \&#39;to channel\&#39; and shodhana means \&#39;purify, cleanse\&#39;, o Hand position Mrigi mudra: It consists of flexing the index and ring fingers of the hand, o Breathing: Gently close the right nostril with the thumb, inhale fingers and exhale slowly through the right. Keeping your right nostril open, inhale, close it, and slowly open and exhale through the left. This is a cycle. Repeat 3-5 times and then release the hand mudra and return to normal breathing.
Study NCT06612138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tai chi exercises
Description: the patients will receive tai chi in the form of Commencing form, Repulse Monkey,Grasp Peacock's Tail,Move Hands like Moving Clouds (left side only), Fair Lady Works at Shuttles, Golden Cock Stands on One Leg (left and right),Brush Knees and Twist Steps, Closing form.
Study NCT06612138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tradional physical therapy
Description: Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
Study NCT06612138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tradional physical therapy
Description: Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
Study NCT06613373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant
Study NCT06119685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Anti-CD38 antibody therapy
Study NCT06613191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participant will be on aspirin alone or P2Y12 inhibitor alone